Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: non-intervention

Registration Number: NCT01877239

Lead Sponsor: Pfizer

Brief Summary: This is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI remission after 24 weeks.

Detailed Description: Non-interventional observational study, national, multicenter prospective non-interventional study (NIS) as defined by the Austrian Drug Law § 2a Section 3 N/A

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 111

Inclusion Criteria

The patient is eligible to receive Etanercept treatment according to the Austrian SmPC.
The decision to treat the patient with Etanercept has been made independently by the physician and is clearly separated from the decision to include the patient in the study. The treatment decision was made in advance and is not dependent on the protocol.
The patient was informed about the study and gave his/her consent and signed an Independent Ethics Committee (IEC) submitted written Informed Consent form on use of the data.
The patient has moderately active RA, defined as a disease activity of CDAI >10 and ≤22 and/or DAS28 (CRP)>3.2 and ≤ 5.1

Exclusion Criteria

Any contraindication according to the Austrian SmPC, which includes:

A hypersensitivity to any component of Etanercept, active tuberculosis or any other serious infection.
Patient has previously participated in this study.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Full Analysis Set	non-intervention	Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24	Week 24	CDAI is a simplified index for assessing the disease activity comprising of the swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI less than equal to (\<=) 2.8 indicates disease remission, greater than (\>) 2.8 to 10 = low disease activity, greater than (\>) 10 to 22 = moderate disease activity, and \>22 = high disease activity. Percentage of participants with CDAI remission (score \<=2.8) at Week 24 were reported.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Clinical Disease Activity Index (CDAI) Status of Disease Activity at Week 12 and Week 52	Week 12 and Week 52	CDAI is a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC, TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity. Percentage of participants with different type of CDAI status of disease activity (remission, low disease, moderate and high disease activity) at Week 12 and 52 were reported. Only those categories in which at least 1 participant had data were reported.
Change From Baseline in Clinical Disease Activity Index (CDAI) Scores at Week 12, Week 24 and Week 52	Baseline, Week 12, Week 24, Week 52	CDAI is a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC, TJC (based on 28-joint assessment), PtGA and PGA (assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity.

Trial Locations

Locations (10): Ordination Dr. Maya Thun
🇦🇹
Wien, Austria
Ordination Dr. Peter Peichl
🇦🇹
Wien, Austria
Rheumazentrum Oberlaa
🇦🇹
Vienna, Austria
Ordination Dr. Thomas Schwingenschlogl
🇦🇹
Wiener Neudorf, Austria
Ordination Dr. Thomas Muller
🇦🇹
Graz, Austria
Ordination Dr. Richard Janetschko
🇦🇹
Linz, Austria
Ordination Dr. Wilhelm Kaiser
🇦🇹
Linz, Austria
Barmherzige Brüder Graz Eggenberg
🇦🇹
Graz, Austria
Ordination Dr. Horst Just
🇦🇹
Klagenfurt, Austria
Dr. Eichbauer-Sturm
🇦🇹
Linz, Austria